secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001157523-24-000253
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q4 net product rev $346M, FY $1.24B (+39%); FY24 guide $1.4-1.5B; HELIOS-B readout late June/early July
--------------------------------------------------------------------------------

- Q4 net product revenue $346M: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.
- Full year 2023 net product revenue $1.24B, up 39% YoY; GAAP net loss per share ($3.52); non-GAAP ($1.61).
- FY24 guidance: combined net product revenue $1.4B-$1.5B, plus collaboration and royalty revenue; operating expense guidance provided.
- HELIOS-B Phase 3 top-line results expected late June or early July; updated statistical analysis plan announced.
- FDA cleared Part B of ALN-APP Phase 1 study at doses up to 180 mg every six months; partial clinical hold remains for higher doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/0001157523-24-000253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/a53896787.htm
  HTML page:      https://secwatch.observer/filing/0001157523-24-000253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer